Fundamental Analysis (FA)
Framework: DCF Benchmarked
Join Palmy To Bypass The Blur →
For XRAY
Valuation Weak
14%
Profitability n.A.
Fin. Growth Balanced
50%
Leverage & Liquidity Bad
0%
Per Share Metrics Bad
0%
Fin. Health n.A.
Fundamental Analysis (FA)
Benchmarked
1 Financial Health
Metric Q4 Q1 Δ in %
Current Ratio 3.29 1.43 1.38
Debt/Assets n.A. n.A. n.A.
Debt/Equity n.A. n.A. n.A.
Net Debt/EBITDA -88.76 13.81 122.81
Naive Interpretation member
2 Per Share
Metric Q4 Q1 Δ in %
Book Value 0.18 15.71 15.68
Cash -19.71 1.40 1.75
Capex 13.93 -0.16 -0.19
Free Cash Flow -92.41 -0.04 0.57
Revenue -4.65 4.59 4.82
Naive Interpretation member
3 Profitability
Metric Q4 Q1 Δ in %
Gross Margin 3.14 0.53 0.52
Operating Margin 251.76 0.06 0.02
ROA -72.20 < 0.005 < 0.005
ROE -72.85 < 0.005 0.02
ROIC 100.00 < 0.005 0.00
Naive Interpretation member
4 Valuation
The "Valuation Entry" for the Focus of XRAY is permitted for members.
5 Growth
The "Growth Entry" for the Focus of XRAY is permitted for members.
6 Leverage & Liquidity
The "Leverage & Liquidity Entry" for the Focus of XRAY is permitted for members.